|Bid||64.07 x 200|
|Ask||64.63 x 100|
|Day's Range||64.12 - 64.64|
|52 Week Range||63.88 - 88.85|
|PE Ratio (TTM)||6.80|
|Dividend & Yield||2.08 (3.24%)|
|1y Target Est||N/A|
Amgen may need to do a major acquisition to revive is stock price longterm
Jim Cramer shares his take on caller favorite stocks, including this drugmaker.
Leerink analyst Geoffrey Porges sees a light at the end of the tunnel for Big Biotech. In a note published today, he predicted that the stocks in his coverage area could shake off the doldrums, and climb 25% to 30% in the next year, if “the group captures a re-rating back to the long term average relative multiple, and our generally positive view of the near and long term revenue and earnings outlook materializes.” That coverage universe includes AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Amgen (AMGN), Biogen (BIIB), Celgene (CELG), Gilead Sciences (GILD), Regeneron (REGN) and Vertex (VRTX). The smaller companies in the group offer the profile of earlier legions of biotech companies, whereas the mature companies in the group (GILD [MP], AMGN [MP], BIIB[MP]) face more near term downside than upside.